Axsome Therapeutics, Inc.
$233.80-6.1%YTD+27.5%1Y+111.1%
Mentions · last 7 days
101+16%
Price updated 2d ago·X counts updated 9h ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $AXSM, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $AXSM.
Biotechnology
No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
What this means for $AXSM
Partial — Commercial CNS biotech with Auvelity approved for major depression and Sunosi for narcolepsy, with CNS pipeline; the GLP-1 pipeline bifurcation and ADA oral formulation competition creates tailwinds for one product line, not the full operation.
Top industry ETF
$IBBiShares Biotechnology ETF
+13.2%YTD
+43.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-63.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-50.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-24.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-0.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
16.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-260%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
92.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
4.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026May 4, 2026$-1.26$-0.85-48.2%
Q4 2025Feb 23, 2026$-0.71$-0.70-1.4%
Q3 2025Nov 3, 2025$-0.94$-0.82-14.6%
Q2 2025Aug 4, 2025$-0.92$-1.00+8.0%
Next earningsMon, Aug 3·consensus EPS $-0.86
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$191.2M+57.4%92.3%-33.1%$-1.26$-20.8M
Q4 FY25$196.0M+65.0%93.7%-15.0%$-0.56$-18.7M
Q3 FY25$171.0M+63.2%93.0%-27.0%$-0.94$988K
Q2 FY25$150.0M+72.1%91.0%-24.5%$-0.97$-32.4M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$984.8M$868.8M – $1.1B-$2.12-$6.06 – -$0.0616
FY27$1.6B$1.2B – $1.8B$5.52-$8.19 – $10.4616
FY28$2.3B$2.3B – $2.3B$14.92-$4.23 – $33.3917
FY29$3.1B$2.6B – $3.7B$25.50$20.03 – $31.5814
FY30$3.8B$3.2B – $4.5B$32.55$25.56 – $40.308
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.93%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+6.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+41.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 43.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KOfficer or director changeJun 98-K — Item 5.02: Officer or director change
AI summary
8-KShareholder voteJun 98-K — Item 5.07: Shareholder vote
AI summary
+ 12 other (4 routine 8-Ks · 2 proxys · 1 10-Q · 1 8-K) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
3 Under-the-Radar Stocks to Buy and HoldBetter Growth Buy: Axsome vs Revolution MedicinesAxsome Begins Phase III Study on Solriamfetol for ADHD in ChildrenAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 2 · last 7 days